Press Releases :: Aerami Therapeutics Holdings, Inc.

Sep 12, 2023 9:48am EDT

Aerami Therapeutics Announces Presentation of Phase 1 Clinical Trial Data for Lead Program AER-901 at the 2023 European Respiratory Society (ERS) International Congress

Jun 01, 2023 8:00am EDT

Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary Hypertension

May 24, 2023 8:58am EDT

Aerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary Hypertension

May 11, 2023 8:00am EDT

Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901 (Inhaled Imatinib) for Pulmonary Hypertension at the 2023 American Thoracic Society (ATS) International Conference

May 05, 2023 7:00am EDT

Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa Yañez

Apr 03, 2023 9:00am EDT

Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2

Feb 23, 2023 9:00am EST

Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress

Jan 05, 2023 9:00am EST

Aerami Therapeutics to Present at Biotech Showcase™ 2023 during the 41st Annual J.P. Morgan Healthcare Conference Week

Dec 21, 2022 8:01am EST

Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Critical Milestone Toward the Planned Initiation of a Phase 2 Trial in Pulmonary Arterial Hypertension (PAH) During the First Half of 2023

Dec 21, 2022 8:00am EST

Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer

rss_feed News RSS